Article
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
Science translational medicine - 7 Jun 2017
Nolan Emma, Savas Peter, Policheni Antonia N, Darcy Phillip K, Vaillant François, Mintoff Christopher P, Dushyanthen Sathana, Mansour Mariam, Pang Jia-Min B, Fox Stephen B, Perou Charles M, Visvader Jane E, Gray Daniel H D, Loi Sherene, Lindeman Geoffrey J
Abstract excerpt
Immune checkpoint inhibitors have emerged as a potent new class of anticancer therapy. They have changed the treatment landscape for a range of tumors, particularly those with a high mutational load. To date, however, modest results have been observed in breast cancer, where tumors are rarely hypermutated. Because BRCA1-associated tumors frequently exhibit a triple-negative phenotype with extensive lymphocyte...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.